2021
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agents
2020
The use of 4F‐PCC to correct direct oral anticoagulant‐induced coagulopathy: An observational analysis
Zheng Y, Tormey CA. The use of 4F‐PCC to correct direct oral anticoagulant‐induced coagulopathy: An observational analysis. Transfusion Medicine 2020, 30: 304-307. PMID: 32342588, DOI: 10.1111/tme.12683.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsThromboembolic eventsFour-factor prothrombin complex concentrateLevel 1 trauma centerAdditional prospective studiesRetrospective observational studyProthrombin complex concentrateOff-label useEmergent surgeryOral anticoagulantsMost patientsClinical outcomesTrauma centerHgb levelsProspective studyLabel indicationsComplex concentrateSevere hemorrhageObservational studyHemorrhage sizePatientsCoagulopathyAdministrationBleedingHemorrhage
2015
Novel Oral Anticoagulants: Efficacy, Laboratory Measurement, and Approaches to Emergent Reversal
Gehrie E, Tormey C. Novel Oral Anticoagulants: Efficacy, Laboratory Measurement, and Approaches to Emergent Reversal. Archives Of Pathology & Laboratory Medicine 2015, 139: 687-92. PMID: 25927153, DOI: 10.5858/arpa.2013-0677-rs.Peer-Reviewed Original ResearchConceptsNovel oral anticoagulantsManagement of NOACOral direct thrombin inhibitorDirect factor Xa inhibitorVitamin K antagonistsDirect thrombin inhibitorFactor Xa inhibitorsCertain clinical circumstancesOral anticoagulationWarfarin effectivenessK antagonistsOral anticoagulantsClinical efficacySafety profileEmergent reversalClinical circumstancesXa inhibitorsUS FoodDrug AdministrationThrombin inhibitorsNew drugsDrugsEfficacyInhibitorsLaboratory assays
2014
Clinical Applications of 4-Factor Prothrombin Complex Concentrate: A Practical Pathologist's Perspective
Unold D, Tormey CA. Clinical Applications of 4-Factor Prothrombin Complex Concentrate: A Practical Pathologist's Perspective. Archives Of Pathology & Laboratory Medicine 2014, 139: 1568-75. PMID: 26619030, DOI: 10.5858/arpa.2014-0366-rs.Peer-Reviewed Original ResearchConceptsProthrombin complex concentrateOral anticoagulantsComplex concentrateVitamin K antagonist reversalVitamin K antagonist therapyNovel oral anticoagulantsSpecific reversal agentsTreatment of hemorrhageDependent coagulation factorsAntagonist therapyLiver diseaseLabel indicationsAntagonist reversalTherapeutic dosesReversal agentsCoagulation factorsBleeding disorderRare coagulopathyVitamin KBlood bankersPathologist's perspectiveClinical applicationAnticoagulantsCoagulopathyBleeding
2013
Pathology Consultation on Monitoring Direct Thrombin Inhibitors and Overcoming Their Effects in Bleeding Patients
Winkler AM, Tormey CA. Pathology Consultation on Monitoring Direct Thrombin Inhibitors and Overcoming Their Effects in Bleeding Patients. American Journal Of Clinical Pathology 2013, 140: 610-622. PMID: 24124139, DOI: 10.1309/ajcp9vjs6kuknchw.Peer-Reviewed Original ResearchConceptsDirect thrombin inhibitorAvailable direct thrombin inhibitorThrombin inhibitorsDegree of anticoagulationLife-threatening bleedsExperimental animal modelsSupportive careBleeding patientsCase reportClinical trialsFactor concentratesRoutine coagulationAnticoagulant effectPharmacologic propertiesAnimal modelsThrombin timeTransfusion productsPathology consultationAnticoagulationDrug concentrationsLaboratory assessmentNewer assaysDrug removalBleedingPrimary author